Company’s Vision
Precision therapies for cardio-kidney-metabolic (CKM) and primary renal diseases
Nephronomics aims to redefine and refine renal disease categories by reconceptualizing traditional diagnostic terms and identifying clinically relevant subtypes within the CKM spectrum. Current renal diagnoses often rely on inconsistently applied laboratory criteria, with biopsies performed only by exception, and frequently reveal unexplored histopathologic findings beyond the primary diagnosis. This evolving understanding reflects how kidney diseases are increasingly recognized as complex conditions intertwined with cardiovascular and metabolic disorders, often against a backdrop of genetic predispositions.
The genetic component of renal disease remains significantly underappreciated in clinical practice. Recent expert consensus suggests that single gene mutations may account for at least 30% of non-diabetic kidney disease cases, while individuals with a first-degree family history of kidney disease face a threefold increased risk of developing chronic kidney disease—yet these critical genetic factors often go unexplored in clinical settings.
Affiliated with Fresenius Medical Care
Nephronomics is a joint venture with the global leader in products and services for individuals with renal diseases, Fresenius Medical Care.
Science
Nephronomics aims to bring precision to renal disease categories by identifying novel genome-phenome associations that can inform targeted therapeutic interventions. By combining whole genome sequencing with comprehensive phenotypic data from ESKD patients who avoided major cardiovascular complications, we work to identify both progression predictors and survival fitness features.
The Nephronomics Atlas is the world’s most robust clinical and genomics renal disease database, consisting of matched whole genome sequencing and longitudinal medical records.
Our database is built on the foundation of My Reason, an IRB-approved research program sponsored by Fresenius Medical Care which has thus far assembled biospecimens and phenotypic data from >33,000 patients.
Integrated Intelligence & AI
The Nephronomics Atlas vertically integrates leading ML and computational biology tools to analyze unstructured text from Electronic Medical Records (EMRs), multi-omics data, and imaging data across a broad patient cohort within the Nephronomics Atlas.
Partnering
Why collaborate with Nephronomics?
We enable discovery and development of next-generation therapeutics:
Precision Medicine & Patient Stratification
Integrating Nephronomics’ rich patient data and ML models enables stratification of patients by cardio-renal profiles and tailor therapies accordingly, addressing heterogeneity in treatment response .
Demonstrating Broader Outcomes
Nephronomics’ cross-disease data can help partners validate and quantify the broader health benefits of its drugs (e.g., obesity drugs beyond weight loss), such as improvements in kidney function or cardiovascular risk markers.
Data-Driven Target Discovery
Nephronomics’ AI-powered CKM database could help uncover new drug targets linking diseases like obesity with kidney and metabolic pathways.
